Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Prostate Cancer Diagnosed Better Using Artificial Intelligence

By LabMedica International staff writers
Posted on 22 Jan 2020
Prostate cancer is a frequently occurring type of cancer, but not always aggressive: more men die with prostate cancer than from prostate cancer. More...
However, its treatment has many consequences for the quality of life of patients, so determining aggressiveness is an important step in choosing a treatment.

To determine the aggressiveness of the cancer, biopsies are taken from the prostate, which are scored by a pathologist. This 'Gleason score' is then used to classify biopsies into five groups - the Gleason Grade Groups - which indicate the risk of dying from prostate cancer. However, this is a subjective process; whether and how a patient is treated may depend on the pathologist who assesses the tissue.

A team of scientists from the Radboud University Medical Center (Nijmegen, The Netherlands) developed an AI system that examines those biopsies the same way a pathologist does. The AI system also determines the Gleason score, and then the system can classify a biopsy according to the Gleason Grade Groups. By means of deep learning, the system examined thousands of images of biopsies to learn what a healthy prostate is, and what more or less aggressive prostate cancer tissue looks like. A semi-automatic labeling technique was used to circumvent the need for manual annotations by pathologists, using pathologists' reports as the reference standard during training. The system was developed to delineate individual glands, assign Gleason growth patterns, and determine the biopsy-level grade.

The investigators collected 5,759 biopsies from 1,243 patients. The developed system achieved a high agreement with the reference standard and scored highly at clinical decision thresholds: benign versus malignant (area under the curve 0.99), grade group of 2 or more (0.978), and grade group of 3 or more (0.974). In an observer experiment, the deep-learning system scored higher (kappa 0.854) than the panel (median kappa 0.819), outperforming 10 of 15 pathologist observers. On the external test dataset, the system obtained a high agreement with the reference standard set independently by two pathologists (quadratic Cohen's kappa 0.723 and 0.707) and within inter-observer variability (kappa 0.71).

The authors concluded that their automated deep-learning system achieved a performance similar to pathologists for Gleason grading and could potentially contribute to prostate cancer diagnosis. The system could potentially assist pathologists by screening biopsies, providing second opinions on grade group, and presenting quantitative measurements of volume percentages. The study was published on January 8, 2020 in the journal The Lancet Oncology.

Related Links:
Radboud University Medical Center


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Gel Cards
DG Gel Cards
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The cell-based tests bring artificial intelligence to transplant outcome care (Photo courtesy of iStock)

AI-Enhanced Cell-Based Blood Tests to Improve Predictive Accuracy for Complex Transplant Outcomes

Managing immunosuppressive drugs in transplant patients is a delicate challenge. Insufficient medication can lead to rejection, which may be cell- or antibody-mediated, while excess immunosuppression raises... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Industry

view channel
Image: Alzheimer’s Association has released its first clinical practice guideline for blood-based biomarker tests (Photo courtesy of Alzheimer’s Association)

New Clinical Guidelines Recommend Use of Blood Tests Instead of Brain Scans for Alzheimer’s Diagnosis

Alzheimer’s disease is a progressive neurodegenerative condition that remains challenging to diagnose early and accurately, particularly in individuals with cognitive impairment. Despite the availability... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.